Clinical Trials
14 trialsNCT00646230 2026-04-14
IV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT06922539 2025-12-15
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
SciTech Development, Inc.
Phase 1 Recruiting
NCT04234048 2025-09-22
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Phase 1 Recruiting
NCT01187810 2022-03-31
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase 1 Terminated
NCT01553071 2022-03-31
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
South Plains Oncology Consortium
Phase 1 Terminated
NCT02163356 2022-03-31
SPOC2013-001
South Plains Oncology Consortium
Phase 1 Terminated
NCT00102635 2018-11-15
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00104923 2017-07-19
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Phase 1 Completed
NCT00003250 2014-04-11
Fenretinide in Treating Patients With Solid Tumors
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00387504 2013-09-12
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
California Cancer Consortium
Phase 1 Completed
NCT00009932 2013-05-15
Combination Chemotherapy in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00003191 2013-02-07
Fenretinide in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005819 2010-06-11
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00001378 2008-03-04
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed